General
Preferred name
GEMIGLIPTIN
Synonyms
LC15-0444 ()
Gemigliptin (tartrate) ()
LC15-0444 (tartrate) ()
Zemiglo, LC15-0444 ()
LC-15-0444 ()
LC-150444 ()
P&D ID
PD073699
CAS
911637-19-9
1374639-74-3
Tags
available
drug
Approved by
KFDA
First approval
2012
Drug indication
Diabetic complication
Type-2 diabetes
Drug Status
investigational
approved
Max Phase
Phase 3
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Gemigliptin is a potent dipeptidyl peptidase-4 (DPP-4) inhibitor with the potential use in diabetes treatment.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
12
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMAP
MedChem Express Bioactive Compound Library
ReFrame library
Selleckchem Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
27
Molecular Weight
489.14
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
3
Aromatic Ring Count
1
cLogP
2.37
TPSA
92.42
Fraction CSP3
0.67
Chiral centers
1.0
Largest ring
6.0
QED
0.66
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
dipeptidyl peptidase inhibitor
Pathway
Metabolic Enzyme/Protease
Target
Dipeptidyl Peptidase
DPP
Source data
